Alexandra S. Zimmer

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

Jung Min Lee, Ashley Cimino‐Mathews, Cody J. Peer et al. · Journal of Clinical Oncology · 2017 · 240 citations

Medicine, Oncology, Pharmacology +17

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget et al. · Clinical Cancer Research · 2020 · 221 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

Jung‐Min Lee, Jayakumar R. Nair, Alexandra S. Zimmer et al. · The Lancet Oncology · 2018 · 212 citations · Full text

Medicine, Gynecology, Oncology +13

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Alexandra S. Zimmer, E. Hitt Nichols, Ashley Cimino‐Mathews et al. · Journal for ImmunoTherapy of Cancer · 2019 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in <i>BRCA</i> Wild-Type, Advanced Triple-Negative Breast Cancer

Margaret E. Gatti‐Mays, Fatima Karzai, Sanaz Soltani et al. · The Oncologist · 2020 · 58 citations · Full text

Medicine, Oncology, Pharmacology +17